First-of-its-Kind vaccine aims to stop cancer before it starts in High-Risk patients
NCT ID NCT07412197
Summary
This study is testing a personalized vaccine designed to prevent cancer in people with Lynch syndrome, a genetic condition that greatly increases cancer risk. The vaccine is made from a person's own immune cells and targets early cancer signals. Researchers will check if the vaccine is safe, can be made reliably, and if it trains the body's immune system to fight off cancer before tumors develop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboudumc
Nijmegen, Netherlands
Contact
Conditions
Explore the condition pages connected to this study.